Citation: Kj. Price et al., PROGNOSTIC INDICATORS FOR BLOOD AND MARROW TRANSPLANT PATIENTS ADMITTED TO AN INTENSIVE-CARE UNIT, American journal of respiratory and critical care medicine, 158(3), 1998, pp. 876-884
Authors:
WRIGHTBROWNE V
SCHNEE AM
JENKINS MA
THALL PF
AGGARWAL BB
TALPAZ M
ESTROV Z
Citation: V. Wrightbrowne et al., SERUM CYTOKINE LEVELS IN INFECTIOUS-MONONUCLEOSIS AT DIAGNOSIS AND CONVALESCENCE, Leukemia & lymphoma, 30(5-6), 1998, pp. 583-589
Citation: Y. Shen et Pf. Thall, PARAMETRIC LIKELIHOODS FOR MULTIPLE NONFATAL COMPETING RISKS AND DEATH, Statistics in medicine, 17(9), 1998, pp. 999-1015
Citation: Pf. Thall et Hg. Sung, SOME EXTENSIONS AND APPLICATIONS OF A BAYESIAN STRATEGY FOR MONITORING MULTIPLE OUTCOMES IN CLINICAL-TRIALS, Statistics in medicine, 17(14), 1998, pp. 1563-1580
Authors:
ESTROV Z
THALL PF
TALPAZ M
ESTEY EH
KANTARJIAN HM
ANDREEFF M
HARRIS D
VAN Q
WALTERSCHEID M
KORNBLAU SM
Citation: Z. Estrov et al., CASPASE-2 AND CASPASE-3 PROTEIN-LEVELS AS PREDICTORS OF SURVIVAL IN ACUTE MYELOGENOUS LEUKEMIA, Blood, 92(9), 1998, pp. 3090-3097
Citation: Pf. Thall et Ke. Russell, A STRATEGY FOR DOSE-FINDING AND SAFETY MONITORING BASED ON EFFICACY AND ADVERSE OUTCOMES IN PHASE I II CLINICAL-TRIALS/, Biometrics, 54(1), 1998, pp. 251-264
Citation: Tb. Dougherty et al., OPTIMAL DOSE OF NALMEFENE IN PATIENTS RECEIVING EPIDURAL FENTANYL ANDDILUTE BUPIVACAINE FOR POSTOPERATIVE PAIN CONTROL, Anesthesiology, 89(3A), 1998, pp. 1145-1145
Citation: Pf. Thall et al., VARIABLE SELECTION IN REGRESSION VIA REPEATED DATA SPLITTING, Journal of computational and graphical statistics, 6(4), 1997, pp. 416-434
Authors:
ESTEY E
THALL PF
PIERCE S
KANTARJIAN H
KEATING M
Citation: E. Estey et al., TREATMENT OF NEWLY-DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA WITHOUT CYTARABINE, Journal of clinical oncology, 15(2), 1997, pp. 483-490
Citation: Pf. Thall et al., NEW STATISTICAL STRATEGY FOR MONITORING SAFETY AND EFFICACY IN SINGLE-ARM CLINICAL-TRIALS, Journal of clinical oncology, 14(1), 1996, pp. 296-303
Authors:
HAMMOUD MA
SAWAYA R
SHI WM
THALL PF
LEEDS NE
Citation: Ma. Hammoud et al., PROGNOSTIC-SIGNIFICANCE OF PREOPERATIVE MRI SCANS IN GLIOBLASTOMA-MULTIFORME, Journal of neuro-oncology, 27(1), 1996, pp. 65-73
Authors:
ESTEY E
THALL PF
MEHTA K
ROSENBLUM M
BREWER T
SIMMONS V
CABANILLAS F
KURZROCK R
LOPEZBERESTEIN G
Citation: E. Estey et al., ALTERATIONS IN TRETINOIN PHARMACOKINETICS FOLLOWING ADMINISTRATION OFLIPOSOMAL ALL-TRANS-RETINOIC ACID, Blood, 87(9), 1996, pp. 3650-3654
Authors:
MAOR MH
LEVIN VA
THALL PF
YUNG WKA
BRUNER J
SAWAYA R
KYRITSIS A
LEEDS N
WOO S
RODRIGUEZ L
GLEASON MJ
Citation: Mh. Maor et al., ACCELERATED RADIATION WITH CONCOMITANT CARBOPLATIN FOR GLIOBLASTOMA-MULTIFORME, European journal of cancer, 31A, 1995, pp. 147-147
Authors:
LEVIN VA
MAOR MH
THALL PF
YUNG WKA
BRUNER J
SAWAYA R
KYRITSIS AP
LEEDS N
WOO S
RODRIGUEZ L
GLEASON MJ
Citation: Va. Levin et al., PHASE-II STUDY OF ACCELERATED FRACTIONATION RADIATION-THERAPY WITH CARBOPLATIN FOLLOWED BY VINCRISTINE CHEMOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA-MULTIFORME, International journal of radiation oncology, biology, physics, 33(2), 1995, pp. 357-364
Citation: R. Simon et al., NEW DESIGNS FOR THE SELECTION OF TREATMENTS TO BE TESTED IN RANDOMIZED CLINICAL-TRIALS, Statistics in medicine, 13(5-7), 1994, pp. 417-429
Citation: Pf. Thall et R. Simon, A BAYESIAN-APPROACH TO ESTABLISHING SAMPLE-SIZE AND MONITORING CRITERIA FOR PHASE-II CLINICAL-TRIALS, Controlled clinical trials, 15(6), 1994, pp. 463-481
Citation: Pf. Thall et Eh. Estey, A BAYESIAN STRATEGY FOR SCREENING CANCER TREATMENTS PRIOR TO PHASE-IICLINICAL-EVALUATION, Statistics in medicine, 12(13), 1993, pp. 1197-1211
Authors:
SEONG DC
KANTARJIAN H
THALL PF
XU J
SUN M
RO J
CHAMPLIN R
TALPAZ M
DEISSEROTH A
SICILIANO MJ
Citation: Dc. Seong et al., REGION-SPECIFIC PAINTING PROBE ON HYPERMETAPHASE PREPARATIONS FOR PH+CELL QUANTITATION, Blood, 82(10), 1993, pp. 10000379-10000379